Literature DB >> 3522621

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt.   

Abstract

Integrated insulin secretion rates calculated from peripheral venous C-peptide measurements by two-compartment kinetic analysis were measured in six young normal subjects after increasing oral glucose loads of 25, 50, and 100 g and respective isoglycemic glucose infusions. The differences in B-cell secretory responses between oral and iv glucose challenges were attributed to factors other than glycemia itself (incretin effect). Both insulin and C-peptide concentrations as well as calculated integrated insulin secretion rates increased with increasing oral glucose loads. Due to the similarity in the glucose profiles after all oral loads, almost identical amounts of iv glucose (approximately 20 g) were infused in all "isoglycemic" infusion experiments, with resulting similar hormone profiles and insulin secretion rates. The percent contribution of incretin factors to total immunoreactive insulin responses after 25, 50, and 100 g glucose (85.6%, 74.9%, and 93.0%; response to oral load, 100%) was significantly higher than their contribution to integrated C-peptide responses (27.6-62.9%) or calculated integrated insulin secretion rates (19.2-61.0%). These findings indicate that the degree of incretin stimulation of insulin secretion depends on the amount of glucose ingested. A discrepancy between the estimates of the incretin effect derived from peripheral venous insulin responses, on the one hand, and C-peptide responses or calculated insulin secretion rates, on the other hand, exists. Inasmuch as peripheral insulin values reflect both insulin secretion and hepatic insulin removal, this discrepancy suggests that elimination kinetics of insulin differ between oral and iv glucose administration. This difference can be related to a significantly reduced fractional hepatic insulin extraction after oral (46.9-54.6%) compared to iv (63.4-76.5%) glucose administration when calculated by a three-compartment kinetic model. This reduction in fractional hepatic insulin extraction could be caused by gastrointestinal factors (hormones or nerves) stimulated in the course of glucose ingestion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3522621     DOI: 10.1210/jcem-63-2-492

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  198 in total

Review 1.  Impact of postprandial glycaemia on health and prevention of disease.

Authors:  E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy
Journal:  Obes Rev       Date:  2012-07-11       Impact factor: 9.213

Review 2.  [GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].

Authors:  Björn A Menge; Juris J Meier; Wolfgang E Schmidt
Journal:  Med Klin (Munich)       Date:  2010-03

Review 3.  The structure and function of the glucagon-like peptide-1 receptor and its ligands.

Authors:  Dan Donnelly
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 4.  Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review.

Authors:  Salvatore Carbone; Dave L Dixon; Leo F Buckley; Antonio Abbate
Journal:  Mayo Clin Proc       Date:  2018-11       Impact factor: 7.616

5.  Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes.

Authors:  D H Jensen; K Aaboe; J E Henriksen; A Vølund; J J Holst; S Madsbad; T Krarup
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

Review 6.  Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling.

Authors:  Charlotte C Ronveaux; Daniel Tomé; Helen E Raybould
Journal:  J Nutr       Date:  2015-02-04       Impact factor: 4.798

7.  Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes.

Authors:  Brenno Astiarraga; Valéria B Chueire; Aglécio L Souza; Ricardo Pereira-Moreira; Sarah Monte Alegre; Andrea Natali; Andrea Tura; Andrea Mari; Ele Ferrannini; Elza Muscelli
Journal:  Diabetologia       Date:  2018-05-07       Impact factor: 10.122

Review 8.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

Review 9.  Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.

Authors:  Ralph A DeFronzo
Journal:  Diabetes Obes Metab       Date:  2017-06-07       Impact factor: 6.577

10.  An explorative study of in vivo digestive starch characteristics and postprandial glucose kinetics of wholemeal wheat bread.

Authors:  Marion G Priebe; Renate E Wachters-Hagedoorn; Janneke A J Heimweg; Alexandra Small; Tom Preston; Henk Elzinga; Frans Stellaard; Roel J Vonk
Journal:  Eur J Nutr       Date:  2008-10-13       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.